Q2 2026 Cryoport, Inc. Earnings Call Transcript
Key Points
- Total revenue reached $49 million in Q2 2026, with Life Science Services segment growing 15% year-over-year, driven by 25% growth in biostorage and bioservices.
- Achieved positive adjusted EBITDA of $400,000, a $1.3 million improvement year-over-year, marking a key milestone in the pathway to profitability.
- Commercial cell and gene therapy support revenue grew 9% to $9.4 million, with services portion up 26% year-over-year as patient treatments in community settings ramp.
- Clinical trial support revenue increased 12% to $13.4 million, with total clinical trials reaching 779 globally, including 94 in Phase 3, and supporting approximately 70% of the industry's trials.
- Operational milestones include launching IntegraCell services in Houston and Liege, onboarding Verismo Therapeutics, and beginning production of cryogenic freezers in China with new smart controllers.
- Generated approximately $5 million in positive net cash from operating activities in the first half of 2026, a $17 million improvement compared to the same period in 2025.
- Life Science Products segment revenue was flat in Q2 2026 due to a strong prior-year comparison, with growth expected to be in the upper single digits for the year.
- Management reiterated full-year 2026 revenue guidance of $192 million to $196 million, citing geopolitical and macroeconomic uncertainties as reasons for prudence.
- China revenue currently represents only 2% to 3% of total revenue, with the company noting that the impact of local production will take time to materialize.
- IntegraCell services are not expected to be a significant revenue contributor in 2026, as industry adoption will take time due to regulatory and SOP hurdles.
- Phase 1 clinical trial starts are softer compared to Phase 2 and Phase 3, indicating a potential slowdown in early-stage pipeline development.
- The company has not yet determined its strategy for expanding services in China, leaving a key growth area uncertain.
Good afternoon, everybody, and welcome to the CryoPort Second Quarter 2026 Earnings Conference Call.
At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session.
If at any time during this call you require immediate assistance, please press *0 for the operator.
This call is being recorded on Thursday, August 6, 2026. I will now turn the conference call over to Mr. Todd Fromer from KCSA Strategic Communications. Please go ahead.
Thank you, operator. Before we begin today, I would like to remind everyone that this conference call contains certain forward-looking statements. All statements that address our operating performance, events, or developments that we expect or anticipated occurring in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and not on information currently available to our management. Our management team believes that these
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
